Haima Therapeutics
Haima Therapeutics is a pre-clinical stage biopharma company focused on developing cell-inspired therapies for the treatment of bleeding and various blood-related diseases. Their lead technology, SynthoPlate, is a novel, fully-synthetic hemostatic agent designed to mitigate bleeding by enhancing the body's natural clotting mechanisms at the site of injury.
Industries
Nr. of Employees
small (1-50)
Haima Therapeutics
11000 Cedar Ave., Ste 280, Cleveland, OH 44106
Products
Synthetic platelet nanoconstruct (IV‑injectable hemostatic agent)
A fully synthetic, intravenously administered nanoparticle therapeutic designed to mimic and amplify platelet adhesion and aggregation to stop bleeding.
Synthetic platelet nanoconstruct (IV‑injectable hemostatic agent)
A fully synthetic, intravenously administered nanoparticle therapeutic designed to mimic and amplify platelet adhesion and aggregation to stop bleeding.
Expertise Areas
- Preclinical development of hemostatic agents
- Biomimetic nanoparticle engineering
- Liposomal and peptide-functionalized nanoconstructs
- Formulation and scale-up for shelf-stable therapeutics
Key Technologies
- Nanoparticle drug delivery
- Liposomal nanoconstructs
- Peptide ligand functionalization for targeted adhesion
- IV‑injectable hemostatic formulations
Investors
National Science Foundation
$949,173 funded.
Announced on 2020-05-16.
National Institutes of Health
$300,000 funded.
Announced on 2019-06-15.
Non Equity Assistance - Haima Therapeutics
Announced on 2019-05-15.
U.S. Department of Defense
$150,000 funded.
Announced on 2018-10-19.
National Science Foundation
$225,000 funded.
Announced on 2018-01-01.
National Science Foundation
$949,173 funded.
Announced on 2020-05-16.
National Institutes of Health
$300,000 funded.
Announced on 2019-06-15.
Non Equity Assistance - Haima Therapeutics
Announced on 2019-05-15.
U.S. Department of Defense
$150,000 funded.
Announced on 2018-10-19.
National Science Foundation
$225,000 funded.
Announced on 2018-01-01.
News & Updates
Announcement of new appointments to the executive team.
Involvement in a significant project aimed at developing blood substitutes.
Announcement of new appointments to the executive team.
Involvement in a significant project aimed at developing blood substitutes.